ContraFect Corporation (CFRXQ)

Market Cap	11.00 -99.8%
Revenue (ttm)	n/a
Net Income	-24.14M
EPS	-5.58
Shares Out	10.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,125
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	n/a
Beta	3.62
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 23
• Stock Exchange: OTCMKTS
• Ticker Symbol: CFRXQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 10, 2026

Data Sources Report a data error